Mineralys Therapeutics, Inc.

MLYS Nasdaq SEC CIK 1933414
Follow Mineralys Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$57.3M −55.2% vs same quarter last year
EPS, diluted −$0.64 −23.1% vs same quarter last year
Operating cash flow −$43.1M −49.3% vs same quarter last year
Operating income −$60.1M −46.1% vs same quarter last year
Net income by quarter
−$48.9M
−$42.2M
−$43.3M
−$36.9M
−$32.2M
−$39.3M
−$241.1M
−$57.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
−$200M−$150M−$100M−$50M$0FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$154.7M
FY24−$177.8M
FY23−$71.9M
FY22−$29.8M
FY21-
Free cash flowOperating cash flow minus capital expenditure
−$200M−$150M−$100M−$50M$0FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$142.4M
FY24−$166.4M
FY23−$81.2M
FY22-
FY21-